ARTICLE | Company News
Non-approvable letter for Zelnorm
June 18, 2001 7:00 AM UTC
Novartis (NVS) and partner Bristol-Myers (BMY) received a non-approvable letter from the FDA for Zelnorm tegaserod to treat abdominal pain, discomfort and constipation in women with irritable bowel sy...